Biospecimen Collection (NCT04840602)

Name: Biospecimen Collection trial for Lymphoplasmacytic Lymphoma (NCT04840602)
Uploaded: 2026-10-31T21:13:33.195Z
Duration: 1 min 15 s
Description: Biospecimen Collection trial for Lymphoplasmacytic Lymphoma (NCT04840602). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04840602.

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma: a one-minute explainerNCT048406021 min

Biospecimen Collection trial for Lymphoplasmacytic Lymphoma (NCT04840602). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with Waldenström macroglobulinemia or lymphoplasmacytic lymphoma requiring treatment and measurable IgM. Prior systemic treatment is excluded, except rituximab completed at least six months earlier.

The idea: compare venetoclax plus rituximab with ibrutinib/rituximab or zanubrutinib alone. Venetoclax blocks BCL-2 survival signals; the other tablets block BTK. Rituximab targets CD20. Treatment runs for up to 24 cycles, with possible crossover after progression.

This phase 2 study plans 92 patients. Sikander Ailawadhi leads the NCI-sponsored study, with 102 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.